Nicotinamide for liver scarring in fatty liver disease
Treatments studied
Part of Digestive system, Hormones & metabolism clinical trials.
This study tests whether nicotinamide (a form of vitamin B3) can help reduce liver scarring in people with nonalcoholic fatty liver disease. You may qualify if you have moderate to severe liver scarring and are between 18 and 85 years old.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have been diagnosed with nonalcoholic fatty liver disease (NAFLD) – fat in the liver not due to alcohol or other causes.
- Your BMI is between 27 and 40 (a measure of body fat).
- A recent FibroScan test (within the last 6 months) showed your liver stiffness is above 9.2 kPa, meaning you have significant scarring (fibrosis).
- You are not a heavy drinker (less than about 2 drinks a day for men, 1 drink for women).
- You do not have serious heart, kidney, or liver diseases that would make the trial unsafe, nor are you taking certain medications like vitamin E, probiotics, or strong diabetes drugs that were started within the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a very low calorie ketogenic diet (a strict low-carb, high-fat diet) can help people with non-alcoholic steatohepatitis (NASH) who have liver scarring. Participants will follow this diet for a year and have two liver biopsies to see if their liver health improves.
This study tests a way to find liver scarring (fibrosis) early in people who have risk factors like being overweight, having type 2 diabetes, or drinking alcohol heavily. Early detection may help prevent serious liver damage.
This study compares two non-invasive approaches to diagnose advanced liver scarring in people with non-alcohol-related fatty liver disease (NAFLD). It may help confirm which test strategy finds advanced scarring without needing a biopsy for everyone.
This study compares two treatments for liver scarring in people with overweight or related health issues. One group follows a special diet with restricted eating times, while the other takes a combination of two medications (naltrexone and bupropion). It aims to see which approach better improves liver fibrosis.
This study tests whether a supplement called nicotinamide riboside (a form of vitamin B3) helps the body burn fat more efficiently during exercise. It may be a good option if you are overweight or have a specific type of diabetes (MODY2) and want to see if a natural supplement can boost your metabolism.
This trial studies whether simvastatin (a cholesterol medicine) can improve or slow scarring of the liver caused by long-term alcohol use. Participants must have confirmed liver fibrosis on biopsy and be in a stable (compensated) phase of liver disease.
Hear when a new Fatty Liver trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.